

Products to Repair and Augment the Skin

Robert Daniels, CEO

r.daniels@elastagen.com





Elastin gives skin its
suppleness and elasticity




Elastin breakdown leads to aged and damaged skin

Teenage boy: cutis laxa

Elastatherapy™



- Improve skin elasticity, thickness and tone
- Synthetic human tropoelastin – the full length, natural building block of elastin
- No chemical cross-linkers – reduced toxicity
- Fine needle delivery for skin repair or skin augmentation
- Multiple formulations to meet a range of aesthetic and medical treatment needs
- GMP / Scale production in place





Elastatherapy™ in Action





Skin cell nuclei

Elastin label



Without Elastatherapy™



With Elastatherapy™

Weiss lab 2011

Current Clinical Program

Trial	Endpoints	Status
ELAPR-P1A – first in man 14 subjects 1 month end point	Upper arm dermis implant to assess safety of three different formulations.	Completed Q1 2011 Elastin products showed excellent safety.
ELAPR-P1B – elastatherapy 16 subjects 6 month end point	'Mesotherapy' application to assess impact on skin elasticity and thickness.	First participant treated in September 2011.
ELAPR-P2 – NLF 30 patients 6 month end point	Treatment of deep skin folds compared to Juvederm.	First participant treatment in December 2011.

- ***Trials covered by current funds***
- ***Trial data confirmed as sufficient to fulfil CE Mark clinical evaluation criteria***

Based on world leading science



Prof Tony Weiss and Research Team – Founding Scientist




- Professor of Biochemistry and Molecular Biotechnology, University of Sydney
- Over 20 years of elastin/tropoelastin research: world leader in the field
- Awards include a Fulbright Fellow, NIH Fogarty International Fellow and Chair of the 2009 Gordon Research Conference on Elastin
- Served on the Australian Biotechnology Advisory Council and is on the Australian Research Council College of Experts

Advised by world leading clinicians

- Drs Alastair and Jean Carruthers (Vancouver, CA)
 - Pioneers of botox use in aesthetics; at forefront of clinical research in US for new aesthetic dermatology products.
- Dr Leslie Baumann (Miami, US)
 - Founder of Baumann Institute; clinical investigator for US pivotal trials of Botulinum toxin and dermal filler products.
- Assoc Prof Greg Goodman (Melbourne, AUS)
 - Lead clinician at Dermatology Institute of Victoria (Australia); primary investigator for Australian & Asia Pacific clinical aesthetic trials
- Dr John Flynn (Gold Coast, AUS)
 - Chair & CEO of Australian College of Cosmetic Surgeons and leading aesthetic clinician in Australia.

Aesthetics – A Growth Market



Elastin: A Unique Product Opportunity



Botulinum Toxin	Hyaluronic Acid	Collagen / Particulate	Elastin
Galderma	Galderma	Aqtis	Elastagen
J&J/Mentor	J&J/Mentor	Valeant	
Medicis	Medicis	Suneva	
Merz	Merz	RMS Bio	
Allergan	Allergan	Merz	
	Anteis		
	Valeant		

M&A Activity Drives Exit

Date	Purchaser	Acquired	Value	Stage
Jul 2011	Valeant	Dermik (Sanofi)	US \$425 Mill	Sales ~\$240 Mill
Dec 2010	Galderma	Q-Med	US \$970 Mill	Sales ~\$200 Mill
Aug 2010	Intendis (Bayer)	Kythera (EU rights only)	US \$43 Mill + \$330 Mill + royalty	Phase II
Feb 2010	Merz	Bioform Medical	US \$253 Mill	Sales ~\$70 Mill
Dec 2009	Allergan	Serica (novel silk biomaterial)	US \$70 Mill	510k approved – pre revenue
Jul 2009	Medicis	Revance (toxin licence)	US \$10 Mill + \$94 Mill + royalty	Preclinical
Dec 2008	J&J	Mentor	US \$1.1 Bill	Sales ~\$350 Mill
Jul 2006	J&J	Colbar	US \$160 Mill	6-month clinical data & CE Mark

Capital Raising Plans

- Series B of \$12-15 Million
- Funds to be raised in second half of 2012
- Triggered by positive data from current clinical trials
- Support launch of aesthetic dermatology products in Europe
- Current investors will participate
- Exit through trade sale or IPO upon CE Mark and early market validation (2014-2015 time frame)

In Summary

- Elastin is critical for youthful, supple, healthy skin and is lost with age, sun damage and injury.
- Elastatherapy™ represents the first treatment to address elastin loss and damage.
- Elastatherapy™ provides a unique, differentiated and proprietary product offering in the high growth aesthetic dermatology market.
- Elastagen will be seeking to raise Series B funding of \$12-15M in 2012 to fund product launch activities.
- Exit opportunities through trade sale or IPO upon CE Mark and early market validation (2014-2015 time frame)